Connexion
E-mail
Mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

Accueil Zonebourse  >  Communauté  >  Forum

Forum

AccueilGénéralActionsIndicesDevisesMatières premièresProduits de BourseActualités 
aouafa dans GENERAL - Il y a 10 ans arrow option
Pharming Group : la biotech 2010
Pharming -- which does not have a product on the market -- has said doubling the authorised share capital and lowering the nominal value of its shares gives the firm "flexibility" ahead of regulatory and commercial events in the EU and North America.

Analyst Bernd Hilhorst at AEK said Pharming has several options for financing: such as returning to a standby equity facility with Yorkville Advisors, issuing convertible debt, or -- as a last resort -- holding a rights issue.

"They have to hurry up and today is a good step to take, but it is only a technicality, and they have to get this done and go back to investors," he said.

Lowering the nominal value of the shares was considered necessary, given that Pharming's share price is currently below the nominal value, preventing it from accessing capital markets.

Pharming's Rhucin treats hereditary angioedema, characterised by acute attacks of painful swelling of the skin, intestine, mouth and throat. In January Pharming said no major concerns had been raised by EMA on its marketing application.

The EMA has twice rejected Pharming's application to market Rhucin, but analysts are confident Pharming's application will be approved this time.

"2010 will be a transformational year for Pharming in which we will make the switch from R&D oriented company to a company with its first product on the market," De Vries said in a statement.

Shareholders also approved on Tuesday the appointment of Rienk Pijpstra as the company's Chief Medical Officer, expanding the management board to four members from the current three. (Reporting by Aaron Gray-Block and Catherine Hornby; Editing by Jon Loades-Carter)
Content Provided by Reuters
Reuters is the largest international news agency -- providing professionals around the world with stories that move the markets.

Pharming’s intellectual property (IP) portfolio contributes to Pharming’s leading role as a player in the field of the production of recombinant proteins in transgenic animals. The company owns and has in-licensed a significant number of patents and patent applications worldwide, broadly covering the technology for the production of recombinant proteins in the milk of transgenic animals, as well as the specific products under development. Protection for recombinant proteins produced in milk as well as methods of generating transgenic animals will last beyond 2020.

Typically, various aspects of manufacturing and use of Pharming’s products are covered by separate patents, thus creating several independent layers of protection around each product. For instance, Pharming’s position in the production and use of Rhucin not only covers the therapeutic compound itself, but also methods of production and purification, improved versions of Rhucin, and therapeutic use in a large number of medical indications, including (but not limited to) HAE and other diseases linked to C1 inhibitor deficiency. Other patents and patent applications cover the recombinant human proteins fibrinogen, lactoferrin, collagen, and the field of DNA repair.

In the field of transgenic technology, Pharming’s portfolio includes the following IP:

Generation and use of transgenic cattle

Milk specific expression in transgenic animals

Animals carrying large transgenes (> 50kb)

Purification of biopharmaceuticals from milk

Structure and design of transgenes for high level production

Fusion proteins for high level expression

Generation of animals using nuclear transfer technology

Oocyte activation for nuclear transfer

Transgenic antibody production

Sperm mediated gene transfer

For applications outside of Pharming’s core activities, this IP is available for licensing.
Home | Info request | Contact us | Careers
faber et 4 autres membres participent à cette discussion
aouafa - Il y a 10 ans arrow option
Une sortie vers le haut 0.43 pourrait mettre le feu aux poudre
Dès l'accord de l'AME, les ventes des produits biotech issu des recherches de l'entreprise depuis 2007 pourrait projeté le titre sur un palier 2007
  
  
faber - Il y a 10 ans arrow option
Ouafa pourquoi diantre en forum general ??????? oups
sous la valeur c est mieux nan??????
merci
1
  
aouafa - Il y a 10 ans arrow option
Le saviez vous? Agreement
Pharming Receives Agreement On Paediatric Investigation Plan For Rhucin(R) From The EMEA Paediatric Committee
Main Category: Arthritis / Rheumatology
Also Included In: Pediatrics / Children's Health
Article Date: 10 Jun 2009 - 1:00 PST

email to a friend printer friendly view / write opinions


Current Article Ratings:

Patient / Public:

Health Professional:

Article Opinions: 0 posts

Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMEA) has adopted an opinion agreeing the paediatric investigation plan (PIP) for Rhucin® (recombinant human C1 inhibitor) in the therapeutic area of immunology-rheumatology transplantation.

"Agreement of the PIP represents a key milestone in Pharming's regulatory plans for the September 2009 submission of the Rhucin marketing authorisation application," said Dr. Bruno Giannetti, COO of Pharming.

According to the EC Regulation 1901/2006 of 12 December 2006, pharmaceutical companies that submit an application for a marketing authorisation for a medicinal product (MAA) in the EU, have to include an approved PIP as part of the regulatory submission.

Source
Pharming Group NV
  
  
faber - Il y a 10 ans arrow option
et ouafa un article de juin 2009
tu deconnes ou quoi ?????????????????????
1
  
aouafa - Il y a 10 ans arrow option
Zut Faber ze croyais me rendre utile: l'intello connait la boite?
Explique nous comment cette biotech a un cours si bas, et argumente nous quelle serait la raison (pour toi) pour qu'elle ne remonte pas a son palier support de 2007

je pense que cela va interessé un bon nombre de personne, amoins que tu as l'info qui justifierait cette baisse
  
  
sirius - Il y a 10 ans arrow option
Il suffit que tu ailles sur la file concernant la valeur, et tu auras toutes les indications nécessaires..Un peu ton habitude, Aouafa, d'ouvrir des posts dans le forum général pour une action, et de nous ressortir des nouvelles d'avant-hier !
1
  
aouafa - Il y a 10 ans arrow option
Tu parles de cette new Zut!
Apr 01, 2010 (M2 EQUITYBITES via COMTEX) --
Biotech company Pharming Group NV (Euronext: PHARM) today announced the publication of preclinical evidence that its recombinant human C1 inhibitor (rhC1INH) was effective in a primate model in preventing antibody-mediated rejection (AMR) following kidney transplantation.

In the published study, Dr Gilles Blancho and colleagues from the Institute of Transplantation - Urology - Nephrology (ITUN) in Nantes, France, demonstrated that Pharming's rhC1INH prevented AMR in a baboon AMR model by blocking the activation of the classical complement system in the treated animals. Untreated animals developed AMR by the second day following transplantation.

Also, histopathological results indicated that the classical complement pathway was effectively inhibited during treatment as evidenced by the lack of specific complement deposition in the kidney, which is also the hallmark of AMR in humans.

Phraming said that the results also confirmed its earlier positive findings with rhC1INH at inhibiting cytotoxicity.

These results are published in Kidney International (advance online publication, 24 March 2010) by Dr Tillou and colleagues.

Comments on this story may be sent to admin@m2.com

For full details on (PHGUF) PHGUF. (PHGUF) has Short Term PowerRatings at TradingMarkets. Details on (PHGUF) Short Term PowerRatings is available at This Link.
  
  
sirius - Il y a 10 ans arrow option
Change de cheval, saute sur Rodriguez, il est encore temps!
  
  
aouafa - Il y a 10 ans arrow option
Conseil blageur , pour conseiller a nos forum te suivre maintenant
neanmoins, je reste fidele a notre elite :)

Consommation de drogue en Europe : un bilan mitigé
Santé publique - 06-11-2009 - 13:09
PartagerRéseaux sociaux
Facebook
MySpace
Twitter
Favoris
FavorisDelicious
Digg
Google
Live

Le « Spice », l'une des drogues en vente sur internet. ©BELGA_AFP_Leon Neal
Une baisse de la consommation de cannabis mais une augmentation légère de la consommation d'héroïne, la drogue la plus meurtrière dans les pays occidentaux : le rapport annuel de l'Observatoire européen des drogues et des toxicomanies (OEDT) présente un bilan 2009 en demi-teinte. La polyconsommation augmente également. Le rapport a été présenté devant la commission des libertés civiles du Parlement européen le 4 novembre.
La consommation de cocaïne et d'héroïne a augmenté en Europe en 2009, selon le rapport. En revanche, la consommation de cannabis a diminué, notamment chez les jeunes. Une première victoire ? Il ne faut pas perdre de vue que l'usage du cannabis reste extrêmement répandu : 2,5 % des jeunes Européens le consomment de façon quotidienne et 74 millions de personnes l'ont déjà essayé au cours de leur vie.



La seconde tendance que révèle le rapport, c'est l'augmentation de la polyconsommation, à savoir la consommation combinée de différentes substances. « Aujourd'hui, les gens deviennent souvent dépendants d'une combinaison de substances légales et illégales », explique Wolfgang Götz, directeur de l'OEDT. Comprenez par là, principalement, la consommation combinée d'alcool et de drogue. Le traitement de telles addictions s'avère plus complexe, précise le directeur de l'OEDT, qui appelle à une prise de conscience de ce problème.


Les chiffres
13 millions d'Européens ont déjà consommé de la cocaïne au cours de leur vie (dont 4 millions au cours de l'année écoulée).
74 millions d'Européens ont déjà consommé du cannabis au cours de leur vie (dont 42 millions ont moins de 35 ans).
2,5 % des jeunes Européens consomment du cannabis quotidiennement.
Un besoin de coopération entre les Etats membres



Comment s'attaquer au problème de la drogue en Europe ? La Néerlandaise Sophia in't Veld (Alliance des démocrates et des libéraux, ALDE), vice-présidente de la commission des libertés civiles du Parlement européen, a pointé du doigt la réticence des Etats membres à partager les résultats de leurs politiques. Elle a souligné la nécessaire coopération dans ce domaine.



Quel rôle pour l'internet ?



Pour la première fois cette année, l'OEDT a analysé la prévention et le traitement sur internet. Elle souligne le potentiel considérable des ces nouvelles approches. Seule ombre au tableau : internet est également un outil de plus en plus utilisé pour vendre et promouvoir les substances psychoactives. Sous le nom « Spice », on peut ainsi trouver sur internet une substance qui, commercialisée comme de l'encens, se fume et produit des effets similaires à ceux du cannabis.



REF. : 20091106STO63968
  
  
trypot - Il y a 10 ans arrow option
D'après mon étude
" 2,5 % des jeunes Européens consomment du cannabis quotidiennement.
Un besoin de coopération entre les Etats membres "

La ou j'allais en cours c t plutôt 25% lol
1
  
aouafa - Il y a 10 ans arrow option
PRODARSAN
Pharming Group N.V. (Pharming) is engaged in the development, manufacture and sale of nutritional products, surgical indications and applications towards the treatment and cure of genetic disorders and ageing diseases. The company’s product line in development stage consists of Recombinant human C1 inhibitor (rhC1INH), Recombinant tissue sealant (rTS), Recombinant human collagen type I (rhCOL) and Recombinant human lactoferrin (hLF). It principally operates in Netherlands and the US. Pharming’s research and development activities are focused on the DNA and Tissue repair. The company is head quartered in Leiden, Netherlands.

During 2009, Prodarsan, a drug for treatment of Cockayne Syndrome was granted orphan drug status by the US FDA. It also anounced that its marketing application for Rhucin will be submitted to the European Medicines Agency (EMEA) in September 2009.

The company reported revenues of (Euro) EUR 0.66 million during the fiscal year ended December 2008, a decrease of 3.77% from 2007. The operating loss of the company was EUR 29.47 million during the fiscal year 2008, as compared to an operating loss of EUR 24.62 million during 2007. The net loss of the company was EUR 26.20 million during the fiscal year 2008, as compared to a net loss of EUR 21.64 million during 2007.
  
  
aouafa - Il y a 10 ans arrow option
Pharming la commercialisation des produits phares est proche
Pharming provides business update
(12/01/10 08:00 CET)





Leiden, The Netherlands, January 12, 2010. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today provided a business update. The Company has made substantial progress on corporate and development targets previously stated in 2009 and is now at a transformational stage with the anticipated approval of its lead product, Rhucin and commercialization partnerships for Rhucin in major territories expected during 2010.


Developments in 2009:
Submission of Marketing Authorization Application (MAA) for Rhucin with the European Medicines Agency (EMA, formerly EMEA) in September as planned

Initiation of pre-BLA process (Biologics License Application) for Rhucin with US FDA in December as planned

Orphan Drug Designation (ODD) and IND (Investigational New Drug) granted for Prodarsan and clinical program for Cockayne Syndrome (CS) indication initiated

Partnering discussions for Rhucin and Lactoferrin ongoing

No milestones received to date from lactoferrin collaboration with Aslan Group AS (Aslan)

Convertible debt reduced from originally EUR70.0 million to EUR10.9 million

Standby Equity Distribution Agreement (SEDA) with YA Global for a total of up to EUR30.0 million in a three year period.




Dr. Sijmen de Vries, Chief Executive Officer of Pharming, said: "This first full year as CEO of Pharming has been a challenging year, however as result of the hard work during this year, 2010 now has the potential to begin to reveal the true value of Pharming's impressive achievements. We have great confidence on the outcome of our European filing and remain on track for BLA filing. In the meantime, we are in advanced discussions with a number of parties for the marketing and sales of Rhucin in major world markets and we expect to secure commercial partnerships and additional financing in the not too distant future. All together, I am looking forward to 2010 with great confidence."




Rhucin progression for HAE and other indications

As planned, Pharming submitted the MAA for Rhucin to EMEA early September 2009. The Day 120 List of Questions (LoQ) is expected end of January 2010. Pharming intends to respond within 3 months (as determined by the standard timetable), after which the review procedure will be continued (Day 121). Pharming may expect the adoption of the final opinion 90 days later (on Day 210). The Company also initiated the pre-BLA process with the US FDA with a pre-BLA meeting held early December as planned. Pharming will provide further updates with respect to progress on the US filing and review process for Rhucin during the first half of 2010.




The development and filing of Rhucin for the treatment of acute HAE attacks has continued to be the key focus. Preparations for development of Rhucin in other indications have progressed with limited resources. Pharming expects to initiate the clinical phase of development of its C1 inhibitor product for applications in the field of transplant indications in 2010.




Prodarsan and DNage

In 2009, Pharming's wholly owned subsidiary DNage BV (DNage) made significant progress with its product Prodarsan for Cockayne Syndrome. In 2009, the FDA granted Prodarsan ODD designation and accepted the IND for Prodarsan to allow the initiation of a clinical study in children suffering from Cockayne Syndrome. Under the IND, DNage initiated an observational study in CS patients. Further clinical Phase II/III studies are expected to commence later in 2010.




Commercial agreements

Rhucin

During the second half of 2009, Pharming has progressed discussions with several international pharma companies with a view to engage partners for the commercialization of Rhucin for major markets, such as the European area (excluding those covered by contracts with Esteve and Eczashibashi) and North America. Pharming expects to be able to conclude one or more commercial deals in the first half of 2010.




Lactoferrin

Due to various regulatory, logistical and legal issues, Aslan Group has not yet started operations in Turkey. As a result, Pharming has not yet received any of the milestones originally planned for 2009. It therefore has decided to identify other parties interested in setting up lactoferrin operations. Discussions with interested parties in Europe and Asia are currently ongoing and are expected to conclude during the first half of 2010. With respect to the lactoferrin GRAS filing in the USA no progress in reviewing the dossier could be reported in 2009. The Company has requested the authorities to stop the review of the file and may re-submit the file with additional data depending on progress in commercial partnerships.




Financial developments

In 2009, Pharming has made considerable progress in its continuing efforts to strengthen its equity position while at the same time decreasing its liabilities and future interest payments. In December 2008 and during 2009, Pharming entered into various agreements with several holders of bonds to reduce the original convertible debt of EUR70.0 million to EUR10.9 million in exchange for EUR8.6 million in cash and a total of 45.1 million newly issued shares.




In April 2009, Pharming signed a EUR20.0 million Standby Equity Distribution Agreement with YA Global with an extension of EUR10.0 million in October 2009. In 2009, the Company started using the SEDA and called a total amount of EUR6.6 million in cash in exchange for the issuance of approximately 11.9 million Pharming shares. As per today, EUR23.4 million of the total EUR30.0 million facility is available. In addition, Pharming secured a short-term convertible debt financing of EUR7.5 million in early January 2010.




The financial results for the full year 2009 will be published on February 18, 2010.




About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming's lead product Rhucin® for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with EMEA. Prodarsan® is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com.




List of used abbreviations

Aslan
Aslan Group AS from Istanbul, Turkey

BLA
Biological License Application

CHMP
Committee for Medicinal Products for Human Use

CS
Cockayne Syndrome

DNage
Pharming's wholly owned subsidiary DNage

EMEA
European Medicines Agency

Esteve
Laboratorios del Dr. Esteve, SA

FDA
US Food and Drug Administration

HAE
Hereditary Angioedema

IND
Investigational New Drug

GRAS
Generally Recognized As Safe

LoQ
List of Questions as part of the European evaluation procedure

MAA
Market Authorization Application

SEDA
Standby Equity Distribution Agreement

YA Global
Yorkville Advisors Global Master SPV LTD




This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.






Contact:


Ms. Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54







HUG#1372413

Press release (PDF)
Fonte : PHARMING GROUP
  
  
aouafa - Il y a 10 ans arrow option
La commercialisation avec SWEDISH ORPHAN
Swedish Orphan Biovitrum And Pharming Sign Rhucin® Distribution Agreement


Stockholm, Sweden and Leiden, The Netherlands – April 15, 2010. – Swedish Orphan Biovitrum (STO: BVT) and Pharming Group NV (NYSE Euronext: PHARM) today announced an exclusive 10 year distribution agreement, under which Swedish Orphan Biovitrum will distribute Rhucin® in 24 EU countries, Norway, Iceland and Switzerland.

Under the agreement, Swedish Orphan Biovitrum will pay to Pharming an undisclosed upfront payment and a regulatory approval milestone. In addition, Swedish Orphan Biovitrum will pay a supply price that will include tiered performance based royalties to Pharming. Swedish Orphan Biovitrum will also have the right to participate in the future development and distribution of Rhucin® in the agreed countries for additional indications.

Rhucin® is a recombinant human C1 inhibitor for the acute treatment of Hereditary Angioedema (HAE) attacks. Pharming submitted an MAA for Rhucin® to the European Medicines Agency (EMA) in September 2009.

"Rhucin® is a novel medicine that offers great value to HAE patients. This orphan drug fits perfectly with our business goals and in our product portfolio. We are very much looking forward to a longstanding partnership with Pharming and the respective growth of both companies. We are delighted to provide what we believe will be a highly beneficial medicine to patients who need it," said Martin Nicklasson, CEO of Swedish Orphan Biovitrum Group.

"We are confident that we will successfully bring Rhucin® through the remainder of the regulatory review process and look forward to making Rhucin® available for HAE patients in Europe shortly thereafter. With their impressive track record in selling and distributing medicines in the rare disease area in Europe, Swedish Orphan Biovitrum makes an ideal partner to maximize the value of our product in a mutually beneficial collaboration," said Dr. Sijmen de Vries, Chief Executive Officer of Pharming.

About Rhucin® (conestat alfa)
Rhucin® or recombinant human C1 inhibitor (rhC1INH) is a recombinant protein for acute treatment of Hereditary Angioedema (HAE) attacks. Rhucin® has identical amino acid sequence as endogenous human C1INH. The safety and efficacy of Rhucin® has been demonstrated in two placebo controlled and four open-label studies. Both randomized placebo-controlled clinical trials showed statistically significant and clinically relevant improvement in time to relief of symptoms and time to minimal symptoms compared to placebo. Rhucin® holds an orphan drug designation both from the US FDA and EMA.

About Hereditary Angioedema
Hereditary Angioedema (HAE) is a debilitating and potentially life-threatening genetic condition, resulting in spontaneous and recurring attacks of angioedema. Angioedema attacks are characterized by swelling of soft tissue in a reaction visually similar to severe allergic reactions. Attacks may affect various locations such as the intestines, the face, extremities or mouth and throat. Without treatment, attacks progress during the first 24 hours and then subside over another two to five days. Attacks are painful and disfiguring and cause significant morbidity. In addition to the life-threatening nature of the disease, quality of life for individuals with the disease may be seriously impaired.

HAE is caused by the lack or deficiency of endogenous C1INH activity, which results in an overreaction of the immune system. Patients typically present in late childhood, with the mean onset at 11 years. The prevalence of HAE is approximately 1 in 30.000 individuals. The frequency of attacks varies significantly in the affected population. Current treatment options include prophylactic treatment with tranexamic acid and androgens, which may reduce the frequency of attacks. The average frequency even under such anabolic steroid prophylaxis is still estimated to be 6-8 treatment requiring attacks per year. For the treatment of acute attacks, the current standard of care in Europe is plasma derived C1 inhibitor from human donors. Swedish Orphan Biovitrum estimates the current value of the European HAE market to approximately €110 million and sees the potential of the HAE market to increase with the introduction of Rhucin® as one of several new treatment alternatives.
  
  
aouafa - Il y a 10 ans arrow option
Un Placement privé pour les investisseurs institutionels
Pharming initiates equity fundraisingNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO

OR IN THE United States, Australia, Canada, Japan or South Africa.

Leiden, The Netherlands, May 27, 2010. Biotech company Pharming Group NV

("Pharming") (NYSE Euronext: PHARM) announced on April 22, 2010 to investigate

the possibilities of attracting additional funding. Today, Pharming announces

that it has received a number of pre-commitments from existing and new

shareholders to participate in an intended equity offering of up to EUR12 million,

by means of a private placement with institutional investors and qualifying

investors who subscribe for a minimum amount of EUR50,000.

The net proceeds of such offering will be used for corporate activities, most

notably for the ongoing regulatory approval processes and start of

commercialization of Rhucin for the treatment of Hereditary Angioedema, and

selective development of subsequent indications of rhC1 inhibitor.

Pharming expects to be able to make further announcements on the intended

offering shortly.
  
  
aouafa - Il y a 10 ans arrow option
A votre bon souvenir !
en 2007, la société Pharming a levé 70 millions par la vente d’obligations convertibles pour 2012.

C’est UBS qui a mené l’opération.

Pharming (Euronext) vient dans le même temps de terminer un accord de redevances avec Paul Capital
Healthcare pour les futurs ventes de ses produits :

Rhucin, pour le traitement de l’angio-oedème (ou oedème de Quincke), héréditaire ; un fibrinogène recombinant pour la cicatrisation des blessures ; un collagène recombinant pour les applications
médicales et industrielles et une lactoferrine recombinante destinée au secteur agroalimentaire.

Les fibrinogènes et collagènes en sont au stade préclinique.
Pharming avait reçu 20 millions de dollars pour l’accord, dont 15 millions en paiement initial.HG
  
  
aouafa - Il y a 10 ans arrow option
PHARMING SOUS L'AILE DE BIOVITRUM presage ...
une future fusion grace a la production du RHUCIN :)

(Rewrites with comments, adds details, updates shares) By Aaron Gray-Block

AMSTERDAM, April 15 (Reuters) - Dutch biotech firm Pharming (PHAR.AS) clinched on Thursday a European distribution deal and an upfront payment for its drug Rhucin with Sweden's Orphan Biovitrum (BVT.ST) as it prepares for its first product launch.

Pharming is waiting for the European Medicines Agency (EMA) to approve the marketing of its lead product Rhucin after previous attempts were turned down. It expects EMA to issue its final opinion in the third quarter of this year.

Pharming shares jumped 11.98 percent to 0.43 euros by 1004 GMT, making it the top gainer in Amsterdam's bourse, whose blue-chip index .AEX was down slightly. Biovitrum shares dipped 1.35 percent.

Orphan Biovitrum will pay Pharming an undisclosed upfront payment and a regulatory approval milestone under the deal to distribute the drug in 24 European Union countries plus Norway, Iceland and Switzerland, the two companies said.

"The fact that Pharming has been able to enter into a new distribution agreement with a financially sound company like Biovitrum is very positive," SNS Securities analyst Martijn den Drijver said.

"It is however unfortunate that no financial details have been provided, as we are still unable to determine whether Pharming still requires additional funding."

Pharming is burning about 2 million euros ($2.73 million) in cash per month and Chief Executive Sijmen de Vries said last month Pharming will need cash soon and is looking at all refinancing options, such as a share placement, a rights issue or partnering deals.

De Vries said the deal with Biovitrum was the first important step towards solidifying Pharming's finances, but other financing steps would still be needed.

De Vries also said it was important that the deal was with a company which had broad infrastructure and experience with specialty drugs.

Under the agreement, Biovitrum will also have the right to participate in the future development and distribution of Rhucin in the agreed countries for additional uses.

"This is a drug which fits perfectly with our overall business strategy ... this is an attractive market and an attractive agreement, and both companies will make a good profit from it," said Erik Kinnman, Biovitrium Executive Vice President.

Biovitrum, has a market cap of $1.3 billion compared with Pharming's 59.3 million euros ($80.1 million), and had pro forma sales of about 2 billion Swedish crowns ($281 million) taking into account its merger with Sweden's Orphan.

In January Pharming said no major concerns had been raised by EMA on its marketing application for Rhucin, which treats hereditary angioedema, characterised by acute attacks of painful swelling of the skin, intestine, mouth and throat. ($1=7.126 Swedish Crown) ($1=.7331 Euro) (Additional reporting by Greg Roumeliotis in Amsterdam and Nick Vinocur in Stockholm; editing by Simon Jessop and Sharon Lindores)
  
  
faber - Il y a 10 ans arrow option
un article du 15 avril lol de lol
fais gaffe aux dates de peremptions des denrées de ton refrigerateur, sinon tu es bon pour une serie de bonnes chiasses.

amusant de te voir reaparaitre le jour meme ou ton ami monaso se fait virer ( monaso pour les nouveaux c est Alex, diabollo et HERBORISTE), celui qui te recommande le plus pour tes articles d avant guerre lol
cette eviction t aurait elle rendu hargneux???????? ou Ouafa ne serait elle pas plutot un nouveau masque
de notre andouille intergalactique.
si ce n est pas le cas, consultes vite pour la cataracte ou pis encore la maladie d'helzeimer, ton cas est semble t il assez lourd, tout a fait a ton image lol
  
  
maldoror - Il y a 10 ans arrow option
Pseudos & clônes
Faber, pour les pseudos ce ne serait pas plutôt :

Monaso = Alex29 = Oscar = Herboriste
Diabollo = Hannibal41
duger74=Likebourse=Merlaio mais curieusement ZBXav semble s'être fait berner par des adresses IP différentes
2
  
aouafa - Il y a 10 ans arrow option
le meilleur est devant nous ! si cela peut ..3615 ULLA j'y suis !
D'après ce communiqué PHARMING annonce avoir réduit en grande partie sa dette qui pénalisait son CA. On peut donc considérer un premier objectif atteint pour la biotech :)

Voici l'article:

Financement
Pharming lève 12 M€ sur fond de refocalisation

La biotech néerlandaise Pharming (NYSE Euronext : PHARM) vient de boucler une recapitalisation pour un montant de 12 M€. Un total de 100 millions de nouveaux titres ont été émis, à un prix unitaire de 0,12 €. Cela portera le nombre d’actions ordinaires de l’entreprise à 272 447 697. « Bien que nous soyons une société particulièrement avancée, le contexte boursier difficile ne nous a pas épargnés pour ce tour, qui a été plus difficile à boucler que les précédents », explique Sijmen de Vries, CEO de Pharming, qui reprend : « Nous avons obtenu le montant que nous escomptions, mais la valorisation reste encore très faible ». Les efforts pour rendre Pharming plus attractive aux yeux des investisseurs ont pourtant été très nombreux depuis l’arrivée de Sijmen de Vries à la tête de la société, en octobre 2008. Après avoir dirigé 4-Antibody et Morphochem, et travaillé pour Novartis ainsi que pour SmithKline Beecham Pharmaceuticals à des postes à responsabilité, ce serial entrepreneur a reçu la mission de conduire un plan de transition pour Pharming dans le but de restructurer la dette de l’entreprise, qui atteignait avant son arrivée près de 70 M€. Un objectif quasi atteint puisque celle-ci n’est aujourd’hui plus que de 10,9 M€.
  
  
aouafa - Il y a 10 ans arrow option
retour sur les projets de recherche, brevets, de Pharming
Le groupe pharmaceutique PHARMING GROUP a été fondé en 1988 aux Pays-Bas et est spécialisé dans le traitement des maladies infantiles. Elle développe et produit ses médicaments essentiellement à base de lait animal, ce qui lui a rapporté un chiffre d’affaires l’an dernier de l’ordre de 660 000 € provenant essentiellement de ses brevets. Au titre du premier trimestre, le groupe a toutefois dévoilé une perte de 6.2 millions d’euros et a stipulé qu’elle aurait besoin de nouvelles sources de financement. Il devrait d’ailleurs recevoir des paiements de la part de MILESTONE dans le cadre de leurs accords partenariaux. Cela permettrait au groupe d’être solidement financée d’ici à 2010.

Concernant ses projets de recherche, le groupe a réussi à faire valider par la FDA (Food and Drug Administration) son médicament « Orphan Drug » pour le traitement du syndrome « Cockayne ». Cette maladie génétique rare concerne les enfants qui souffrent d’un vieillissement accéléré tout en développant des maladies graves. Cette agrémentation a catalysé la reprise de l’action PHARMING GROUP qui, introduit proche des 10 EUR, avait beaucoup de mal à se ressaisir.
  
  
arnange - Il y a 10 ans arrow option
Aouafa s'il te plait arrête de nous ressortir des notes..
qui datent d'il y a un peu plus d'un an ! C'est franchement pénible !!! D'avance merci.
1
  
aouafa - Il y a 10 ans arrow option
SOLVAY ET PHARMING= UNE COLLABORATION
info du jour

echo.be
  
  
aouafa - Il y a 10 ans arrow option
Reprise technique !
STRATEGIE

Au dessus de 1,44 EUR AGEAS (ex. FORTIS) se dirige à court terme vers 2,37 EUR.Sous 1,44 EUR le mouvement s'inverserait pour une correction vers 1,25 EUR.

SYNTHESE

Le MACD est négatif, mais il se situe au-dessus de sa ligne de signal : la tendance est en train de changer. Maintenant, le MACD doit franchir zéro pour que la hausse se poursuive dans les jours à venir. L'indicateur principal de la force du mouvement (RSI) montre que la situation technique est assez saine car il n'y a pas de surachat. Les indicateurs stochastiques ne donnent pas de signaux clairs pour les jours à venir. Les volumes échangés sont supérieurs à la moyenne des volumes sur les 10 derniers jours.

MOUVEMENTS ET NIVEAUX

Depuis le plus bas à 1,79 EUR le titre est en phase de reprise technique vers sa moyenne mobile à 50 jours située à 2,23 EUR : le comportement des cours sur ce niveau permettra d'envisager la poursuite du mouvement à moyen terme. Pour alléger la position, on pourra attendre de tester les résistances à court terme situées à 2,37 EUR et 2,56 EUR. Les supports sont à 1,62 EUR puis à 1,44 EUR .

Copyright 2010 TEC - Tous droits de reproduction et de représentation réservés. TEC est une analyse de la situation technique d'un actif à un instant donné et qui est susceptible de changer à tout moment. Les notions de support et de résistance sont issues des principes élémentaires de l'analyse technique. Ces informations indicatives ne constituent en aucune manière une incitation à vendre ou à acheter. Le lecteur reste seul responsable de leur interprétation et de l'utilisation des informations mises à sa disposition.
  
  
aouafa - Il y a 10 ans arrow option
Commnunique de Pharming: 15 juin 2010
Pharming Provides Background Information On Recently Completed Private Offering


Leiden, The Netherlands, June 15, 2010. Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) today announced that it has responded to a letter from the Dutch Association for Private Investors (Vereniging Van Effectenbezitters or “VEB”) to provide additional information to its shareholders on the recently completed offering of new shares.

The VEB is a Dutch organization which represents the interest of private investors. On June 2, 2010, Pharming received a letter from the VEB in which they requested additional information on the recently completed issue of 100 million new Pharming shares, as announced on May 28, 2010. Pharming’s management has responded to these questions on June 9, 2010. Both letters are in Dutch and can be found on the website of the VEB at www.veb.net. The complete list of questions and answers in Dutch and English can be found on Pharming’s website: www.pharming.com > Investor Relations > Public Reports > Equity Fundraising May 2010.

About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming’s lead product Rhucin® for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with the European Medicines Agency. Prodarsan® - a product under development by Pharming's subsidiary DNage - is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Recently the partial spin-out of DNage was initiated. Additional information is available on the Pharming website, http://www.pharming.com.

Contact:
Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54 or E: m.vanhelmond@pharming.com
  
  
aouafa - Il y a 10 ans arrow option
A mes fidèles admirateurs:
Company Information on Pharming Group


Sector Healthcare
Rating Accumulate
Reuters code PHAR.AS
Bloomberg code PHARM NA
Latest share price 0.21 EUR (+0.00) @ 18/06/2010 08:04
Price target 0.30
Latest update Research Morning Note for 08/06/2010 available HTML and PDF
Analyst Martijn den Drijver, Companies covered by this analyst
Analyst phone# +31 20 550 8636
Current Opinion To accept a EUR 0.12 share price in the private placement was a necessary evil but provided crucial cash to fund operations until EU approval is obtained. This approval, combined with funding from YA global and EU+US partner milestones means that although the risk profile is still high, it is clearly improving
Website www.pharming.com
Company Description Pharming Group is a Dutch based Biotechnology company. The company has two proprietary technologies platforms for the discovery and production of drugs: transgenic technology and DNA repair technology. Currently, Pharming has one late-stage product Rhucin, for the treatment of acute attacks of Hereditary Angioedema.
Profit Guidance Pharming does not provide a financial outlook
End financial year 31/12/2010
Major shareholders Lafferty Limited: 11%;UBS: 8.3%;Van Herk Group: 4.9%;: 0%;: 0%;
SNS Securities acts as a liquidity provider for the company and has
  
  
aouafa - Il y a 10 ans arrow option
je vous laisse le soin de traduire : c'est tout bon
18 jun 10 Pharming breidt uitstaande aandelen uit
LEIDEN (AFN) - Biotechnologiebedrijf Pharming heeft het aantal uitstaande aandelen met ruim 8 miljoen uitgebreid tot 277.206.421 aandelen. Dat maakte het bedrijf vrijdag bekend.De uitbreiding hangt samen met de conversie van in januari 2010 uitgebrachte obligaties. Dor de omwisseling daarvan in aandelen daalde de waarde van die obligaties van 7,5 miljoen euro tot 2 miljoen euro.
  
  
aouafa - Il y a 10 ans arrow option
http://www.veb.net
15.06.2010 08:05
Pharming Group N.V.: Pharming provides background information on recently completed private offering
Leiden, The Netherlands, June 15, 2010. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that it has responded to a letter from the Dutch Association for Private Investors (Vereniging Van Effectenbezitters or "VEB") to provide additional information to its shareholders on the recently completed offering of new shares.

http://www.finanznachrichten.de/nachrichten-2010-06/17153932-pharming-group-n-v-pharming-provides-background-information-on-recently-completed-private-offering-399.htm



The VEB is a Dutch organization which represents the interest of private investors. On June 2, 2010, Pharming received a letter from the VEB in which they requested additional information on the recently completed issue of 100 million new Pharming shares, as announced on May 28, 2010. Pharming's management has responded to these questions on June 9, 2010. Both letters are in Dutch and can be found on the website of the VEB at www.veb.net (http://www.veb.net). The complete list of questions and answers in Dutch and English can be found on Pharming's website: www.pharming.com (http://www.pharming.com) > Investor Relations > Public Reports > Equity Fundraising May 2010.
  
  
aouafa - Il y a 10 ans arrow option
Un titre qui s'agite et bien d'actualité
mes fideles lecteurs le savent bien
  
  
faber - Il y a 10 ans arrow option
et ta soeur elle s'agite ?????? lol
"mes fideles lecteurs" lol de lol pour lire quoi?????? " mes fideles admirateurs" lol ( mon chien quand il pâsse devant la vitrine du charcutier, il regarde aussi les andouilles, mais ne les admire pas pour autant)

tes posts sont aussi performants que les stroumpfs gaziers qui poussaient la baballe. aussi steriles que le lac rose.

fais toi un blog pour tes fideles lecteurs lol

emmene avec toi tes doubles ABC €£YS€ et les autres
sur abc, ton "fidele lecteur" bruncho avait comme qui dirait l air de se foutre de ta fiolle. nan?????
on dirait que la bas aussi tu es catalogué.

ou tu superformes, chose sur, .......................... dans la betise et l'égo sur dimensionné

tu n es pas vexé au moins ???????? nan !!!!!!!! me voila rassuré car en fait j ai horreur de trainer les andouilles dans la farine....................................... mais certaines insistent alors GO GO GO.
  
  
Voir les 29 réponses précédentes
aouafa - Il y a 10 ans arrow option
Faber quel enthousiasme ! Pourtant cette info mérite ...
HAE est provoqué par le manque ou l'insuffisance de l'activité endogène de C1INH, qui a comme conséquence une réaction exagérée du système immunitaire. Patients en général présents dans l'enfance en retard, avec le début moyen à 11 ans. La prédominance de HAE est approximativement 1 dans 30.000 individus. La fréquence des attaques varie de manière significative dans la population affectée. Les options courantes de traitement incluent le traitement prophylactique avec de l'acide et les androgènes tranexamic, qui peuvent réduire la fréquence des attaques. La fréquence moyenne même sous un tel stéroïde anabolique on estime encore à que la prophylaxie le traitement 6-8 exigeant des attaques par an. Pour le traitement des attaques aiguës, le niveau du soin courant en Europe est l'inhibiteur C1 dérivé par plasma des donateurs humains. L'International orphelin suédois de Biovitrum estime la valeur courante du marché européen de HAE approximativement à €110 million et voit le potentiel du marché de HAE d'augmenter avec l'introduction de Rhucin® en tant qu'une de plusieurs nouvelles solutions de rechange de traitement.
  
  
faber - Il y a 10 ans arrow option
en effet 13% de baisse et la precedente pas mieux mdr
j en parlerai a €£YS€ a l occasion
tes "fideles lecteurs" ont plus a cette heure envie de te botter le cul.
tu es blindé en pharming lol, chacun sait que depuis l echec de la mm150 a 44 ct, ta pouliche est bonne pour l abattoir , trop carne pour en faire du steack , à l'équarrissage direct

une lecture chaudement recommandée " l'analyse technique pour les nuls" aux editions Napoli
tu verras il y a tout plein de jolies photos, montagnes, plaines, piste noire de skis ( celle de pharm).

quant comprendras tu que les posts se mettent sous la valeur, ???
  
  
aouafa - Il y a 10 ans arrow option
La baisse des places est lié au crainte economique lié aux dettes bancaires
Quelque soient les places certains titres ont résisté malgré les stats du jour:

28/06 19:21Zone euro : dégradation du climat des affaires en …
28/06 18:40La réévaluation du renmibi profitera à d'autres de…
28/06 18:04L'euro va continuer sa baisse face à un dollar so…
28/06 15:19Taux limite de déduction des intérêts des comptes …
28/06 15:01Yannick Murat rejoint le conseil en investissemen…

Ces titres ont résistés grace au retour de la confiance des investisseurs sur des secteurs qui resiste a la crise.

En ce qui concerne notre pépite , les investisseurs l'ont shorté à tort , par craintre et manque de confiance sur le titre.
Mais je te remercie de te soucier de mon portefeuille qui grossit avec le temps par des rachats a bon compte.

Quel est ton PRU ? surement Négatif pour la denigrer ainsi :)
  
  
faber - Il y a 10 ans arrow option
MDR mon dieu qu il est stupide
il est de noToriete publique que les p)laces ont reculé de 13% et de 30% depuis 8 jours

une merde de chien peinte en doré ne fera jamais une "pepité" aie aie pepito

ta phaming, une pepite!!!!!!!!!! elle ressemble plutot a un suppositoire , Pharm pour 10000 actions fournira
a tes lecteurs fideles un tube de vaseline, voir de cicatrisant. car il vont vous la mettre profond. chacun son truc, il y en a qui aime
s il y en a qui shortent comme nous dit l auguste, c est grace a des credules de ton genre et a ses fans mdr.
pose toi la question.
fait un effort et essaye de rentrer ca dans ta petite tete mon gars, sinon tu vas avoir du mal a marcher.
autre solution radicale............................ la corde.

ps quant ta daube sera a 4 cts, reveilles nous, si on a 100E a perdre, on y songera ( et encore je prefere en faire don a la croix rouge lol)

aouafa ressaisis toi, sinon tu vas tantot appartenir à la caste charcutiere que j affectionne .

au fait pour ta gouverne, depuis le rejet des 44, non seulement j ai soldé positif et shorté histoire de mettre un peu d 'epinards dans la creme fraiche.
vois tu je prefere ces temps ci du turbo cac avec du 30% de PV en dailly,, mieux que du 30% negatif sur une semaine nan ???????

en AT tu es nul et en analyse fondamentale tout aussi nul , en copier coller tu excelles .
tu as du travail avant de commencer a trader au réel.

n oublies pas de percer ta chaise tant que tu es valide, parce que tu vas avoir terriblement mal. aie aie
mes amitiés a €lys€
un service, ne crie pas trop fort lors de " l'operation", vu que pour rien tu nous gaves, mieux vaut prevenir
  
  
faber - Il y a 10 ans arrow option
ou est tu ????? alors ????? toujours aussi piquousé
notre ami, sur un autre forum sous le pseudo ELYSE, cassait du " BASHER" ( une explosion sur des objectifs
surréealiste allait, pour reprendre ses propos, clouer le bec au bashers)
a cette heure, ce serait plutot notre vendeur de mirroir aux allouettes qui aurait le bec cloué nan ????????
pharm etait alors a 30 cts
resultat 40% in the baba en qq jours .

Le graphe d apres l homme etait evocateur d un mega up , et le matraquage de nouvelles vieilles de plusieurs semaines ou mois n'a rien fait pour enrayer la chute inexorable de la valeur

Rendez vous sur ground 14 cts et sans doute 10 cts. pour la " PEPITE"
  
  
  • Publier
    loader